Surmodics Reports Q3 2025 Results: Revenue Declines Amid Improved Losses and R&D Efficiencies

Surmodics, Inc. (NASDAQ: SRDX) reported its quarterly financial results for the period ending June 30, 2025. Below are the key highlights from the income statement and other critical developments within the company.

• Revenue: Total revenue decreased to $29.6 million in Q3 2025, down 3% from $30.3 million in Q3 2024.
• Product Sales: The product sales segment generated $16.8 million, reflecting an 11% decline from the previous year.
• Operating Costs: Total operating expenses were $34.8 million, slightly lower than $35.7 million in Q3 2024.
• Operating Loss: The operating loss was $5.2 million, improved from a loss of $5.4 million in Q3 2024.
• Net Loss: The company reported a net loss of $5.3 million, compared to a net loss of $7.6 million in the same quarter last year.
• Basic Loss Per Share: Loss per share was $(0.37), an improvement from $(0.53) in Q3 2024.

Positive Aspects:

• Costs related to research and development (R&D) decreased significantly, down 22% in Q3 2025 compared to the prior year.
• In Vitro Diagnostics revenue showed a stable growth of 6%, highlighting efficiency in that segment despite overall revenue declines.
• Merger Agreement signed in May 2024 for cash acquisition at $43.00 per share, suggesting potential future valuation improvement.

Negative Aspects:

• Medical Device product sales saw a substantial decline of 19% in the nine-month period ending in Q3 2025, primarily due to reduced shipments of the SurVeil DCB.
• Significant increase in selling, general, and administrative (SG&A) expenses due to merger-related charges, impacting profitability visibility.
• Cash flow from operations was negative at $(5.5) million for the nine months ended June 30, 2025, an increase in cash outflow compared to $(3.4) million in the prior-year period.

Key Financial Metrics:

• Research and Development Expenses: $7.57 million (Q3 2025)
• Cash and Cash Equivalents: $26.28 million as of June 30, 2025, down from $36.12 million at September 30, 2024.
• Long-term Debt: $29.66 million, slightly increased from $29.55 million a year prior.

In summary, while Surmodics, Inc. (NASDAQ: SRDX) is navigating a challenging revenue environment, the company is working through significant R&D efficiencies and preparing for an acquisition that could reshape its trajectory. However, continued scrutiny on cash flows and product sales performance remains critical for investors and stakeholders.